Bruker's Preliminary Q2 Revenues Miss Estimates, Stock Tumbles | GenomeWeb

NEW YORK (GenomeWeb News) – Bruker today announced preliminary second-quarter revenues of $420 million, falling short of analyst estimates of $434.5 million.

The company posted revenues of $401.2 million a year ago. Bruker is scheduled to report its second-quarter earnings on July 31.

Bruker added that EPS for the second quarter is expected to be in the range of $.05 and $.07, while adjusted EPS is expected to fall between $.11 and $.13, which would also miss a consensus Wall Street estimate of $.21.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.